Pixantrone meets goal in pivotal lymphoma trial
This article was originally published in Scrip
Executive Summary
Cell Therapeutics' experimental chemotherapy drug pixantrone has met its primary endpoint in its first pivotal Phase III trial, EXTEND, in patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL). The Seattle-based company expects to start the filing of the drug with the US FDA in early 2009.